Early events in the molecular pathogenesis of lung cancer

Cancer Prevention Research

Volumn 9, Issue 7, 2016, Pages 518-527

  Kadara, Humam ^a,b   Scheet, Paul ^a,b   Wistuba, Ignacio I ^a   Spira, Avrum E ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; PROTEIN; PROTEIN KINASE LKB1; RNF20 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR SOX2; TSC1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; TUMOR MARKER;

CANCER DIAGNOSIS; CARCINOMA IN SITU; EARLY DIAGNOSIS; HUMAN; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; MOLECULAR PATHOLOGY; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL LUNG CARCINOMA; ANIMAL; EARLY CANCER DIAGNOSIS; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PRECANCEROUS CONDITIONS; PROCEDURES; TRENDS;

ANIMALS; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; PRECANCEROUS CONDITIONS;

EID: 84977120272     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0400     Document Type: Review

References (143)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
3. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet 2011; 378: 1727-40.
4. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367-80.
5. Kanodra NM, Silvestri GA, Tanner NT. Screening and early detection efforts in lung cancer. Cancer 2015; 121: 1347-56.
6. Keith RL, Miller YE. Lung cancer chemoprevention: Current status and future prospects. Nat Rev Clin Oncol 2013; 10: 334-43.
7. Spira A, Halmos B, Powell CA. Update in Lung Cancer 2014. Am J Respir Crit Care Med 2015; 192: 283-94.
8. Szabo E, Mao JT, Lam S, Reid ME, Keith RL. Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: E40S-60S.
9. Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: An overview for clinicians. CA Cancer J Clin 2014; 64: 272-90.
10. Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol 2006; 1: 331-48.
11. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010; 29: 23-36.
12. Colby TV, Wistuba II, Gazdar A. Precursors to pulmonary neoplasia. Adv Anat Pathol 1998; 5: 205-15.
13. Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol 2001; 54: 257-71.
14. Kadara H, Wistuba II. Field cancerization in non-small cell lung cancer: Implications in disease pathogenesis. Proc Am Thorac Soc 2012; 9: 38-42.
15. Steiling K, Ryan J, Brody JS, Spira A. The field of tissue injury in the lung and airway. Cancer Prev Res 2008; 1: 396-403.
16. Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res 2011; 4: 962-72.
17. Greenberg AK, Tsay JC, Tchou-Wong KM, Jorgensen A, Rom WN. Chemoprevention of lung cancer: Prospects and disappointments in human clinical trials. Cancers 2013; 5: 131-48.
18. Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A. Bridging the clinical gaps: Genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med 2013; 11: 168.
19. Cho KR, Vogelstein B. Suppressor gene alterations in the colorectal adenoma-carcinoma sequence. J Cell Biochem Suppl 1992; 16G: 137-41.
20. Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992; 70: 1727-31.
21. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
22. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999; 18: 643-50.
23. Yuspa SH. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis-thirty-third G. H. A. ClowesMemorial Award Lecture. Cancer Res 1994; 54: 1178-89.
24. Westra WH. Early glandular neoplasia of the lung. Respir Res 2000; 1: 163-9.
25. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus GJ, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996; 56: 2224-8.
26. Carr LL, Chung JH, Duarte Achcar R, Lesic Z, Rho JY, Yagihashi K, et al. The clinical course of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Chest 2015; 147: 415-22.
27. Yatabe Y, Borczuk AC, Powell CA. Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer 2011; 74: 7-11.
28. MounawarM, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 2007; 67: 5667-72.
29. Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, et al. Lung cancer in never smokers: Molecular profiles and therapeutic implications. Clin Cancer Res 2009; 15: 5646-61.
30. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46.
31. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-A different disease. Nat Rev Cancer 2007; 7: 778-90.
32. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-20.
33. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Taniere P, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: Distinct patterns in never, former, and current smokers. Cancer Res 2005; 65: 5076-83.
34. Ridanpaa M, Karjalainen A, Anttila S, Vainio H, Husgafvelpursiainen K. Genetic alterations in p53 and k-ras in lung-cancer in relation to histopathology of the tumor and smoking history of the patient. Int J Oncol 1994; 5: 1109-17.
35. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988; 48: 5738-41.
36. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543-50.
37. Govindan R,Ding L,GriffithM, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and neversmokers. Cell 2012; 150: 1121-34.
38. Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol 2015; 16: E342-51.
39. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-35.
40. Desai TJ, Brownfield DG, KrasnowMA. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 2014; 507: 190-4.
41. Mainardi S, Mijimolle N, Francoz S, Vicente-Duenas C, Sanchez-Garcia I, Barbacid M. Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci U S A 2014; 111: 255-60.
42. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.
43. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002; 26: 767-73.
44. Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005; 65: 7568-72.
45. Tang X, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran C, et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res 2008; 1: 192-200.
46. Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol 1999; 111: 610-22.
47. Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E. Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol 2003; 120: 712-9.
48. Tominaga M, Sueoka N, Irie K, Iwanaga K, Tokunaga O, Hayashi S, et al. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67. Lung Cancer 2003; 40: 45-53.
49. Takamochi K, Ogura T, Suzuki K, Kawasaki H, Kurashima Y, Yokose T, et al. Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinomaof the lung. Am J Pathol 2001; 159: 1941-8.
50. Ghaffar H, Sahin F, Sanchez-CepedesM, Su GH, ZahurakM, Sidransky D, et al. LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res 2003; 9: 2998-3003.
51. Selamat SA, Galler JS, Joshi AD, FyfeMN, CampanM, Siegmund KD, et al. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One 2011; 6: E21443.
52. Minoo P, Su G, Drum H, Bringas P, Kimura S. Defects in tracheoesophageal and lung morphogenesis in Nkx2.1(-/-) mouse embryos. Dev Biol 1999; 209: 60-71.
53. Yuan B, Li C, Kimura S, Engelhardt RT, Smith BR, Minoo P. Inhibition of distal lung morphogenesis in Nkx2.1(-/-) embryos. Dev Dyn 2000; 217: 180-90.
54. Kimura S,Hara Y, Pineau T, Fernandez-Salguero P, Fox CH, Ward JM, et al. The T/ebp null mouse: Thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev 1996; 10: 60-9.
55. Ikeda K, Clark JC, Shaw-White JR, Stahlman MT, Boutell CJ, Whitsett JA. Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J Biol Chem 1995; 270: 8108-14.
56. Kwei KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, Salari K, et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008; 27: 3635-40.
57. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma.Nature 2007; 450: 893-8.
58. Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007; 67: 6007-11.
59. Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011; 473: 101-4.
60. Park IW, Wistuba II, Maitra A, Milchgrub S, Virmani AK, Minna JD, et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst 1999; 91: 1863-8.
61. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60: 1949-60.
62. Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, et al. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999; 59: 1973-9.
63. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrantmethylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998; 95: 11891-6.
64. Merrick DT, Haney J, Petrunich S, Sugita M, Miller YE, Keith RL, et al. Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis. Lung Cancer 2005; 48: 31-45.
65. Keith RL, Miller YE, Gemmill RM, Drabkin HA, Dempsey EC, Kennedy TC, et al. Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 2000; 6: 1616-25.
66. Hirsch FR, Prindiville SA, Miller YE, Franklin WA, Dempsey EC, Murphy JR, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: A randomized study. J Natl Cancer Inst 2001; 93: 1385-91.
67. Hirsch FR, Lippman SM. Advances in the biology of lung cancer chemoprevention. J Clin Oncol 2005; 23: 3186-97.
68. Khuri FR, Cohen V. Molecularly targeted approaches to the chemoprevention of lung cancer. Clin Cancer Res 2004; 10: 4249s-53s.
69. Bass AJ,Watanabe H,Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41: 1238-42.
70. Hussenet T, Dali S, Exinger J, Monga B, Jost B,Dembele D, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 2010; 5: E8960.
71. Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL, et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One 2010; 5: E11022.
72. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, et al. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer 2011; 104: 1410-7.
73. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, et al. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 2010; 5: E9112.
74. McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M, et al. Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med 2010; 182: 83-91.
75. Nakachi I, Rice JL, Coldren CD, Edwards MG, Stearman RS, Glidewell SC, et al. Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions. Cancer Prev Res 2014; 7: 255-65.
76. Ooi AT, Gower AC, Zhang KX, Vick JL, Hong L, Nagao B, et al. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res 2014; 7: 487-95.
77. Wistuba II, Berry J, Behrens C,Maitra A, ShivapurkarN,Milchgrub S, et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res 2000; 6: 2604-10.
78. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003; 4: 181-9.
79. Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN,Mahjoub MR, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med 2011; 17: 1504-8.
80. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in smallcell lung cancer. Nature 2003; 422: 313-7.
81. Peifer M, Fernandez-Cuesta L, SosML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44: 1104-10.
82. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012; 2: 798-811.
83. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 2013; 19: 6322-8.
84. Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 2015; 28: 57-69.
85. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
86. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res 2003; 63: 1727-30.
87. Gomperts BN, Spira A, Massion PP, Walser TC, Wistuba II,Minna JD, et al. Evolving concepts in lung carcinogenesis. Sem Respir Crit Care Med 2011; 32: 32-43.
88. Graham TA, McDonald SA,Wright NA. Field cancerization in the GI tract. Future Oncol 2011; 7: 981-93.
89. Auerbach O, Stout AP, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961; 265: 253-67.
90. Beane J, Sebastiani P, LiuG, Brody JS, Lenburg ME, Spira A. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol 2007; 8: R201.
91. Hackett NR, Heguy A, Harvey BG, O'Connor TP, Luettich K, Flieder DB, et al. Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. Am J Respir Cell Mol Biol 2003; 29: 331-43.
92. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997; 89: 857-62.
93. Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A 2004; 101: 10143-8.
94. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007; 13: 361-6.
95. Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997; 89: 1366-73.
96. Gomperts BN, Walser TC, Spira A, Dubinett SM. Enriching the molecular definition of the airway "field of cancerization: " establishing new paradigms for the patient at risk for lung cancer. Cancer Prev Res 2013; 6: 4-7.
97. Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, et al. Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J Natl Cancer Inst 2014; 106: Dju004.
98. Nelson MA, Wymer J, Clements N, Jr. Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers. Cancer Lett 1996; 103: 115-21.
99. Franklin WA, Gazdar AF,Haney J, Wistuba II, La Rosa FG, Kennedy T, et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest 1997; 100: 2133-7.
100. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002; 62: 2370-7.
101. Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong WK, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 2002; 62: 351-5.
102. Zochbauer-Muller S, Lam S, Toyooka S, Virmani AK, ToyookaKO, Seidl S, et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 2003; 107: 612-6.
103. Gesthalter YB, Vick J, Steiling K, Spira A. Translating the transcriptome into tools for the early detection and prevention of lung cancer. Thorax 2015; 70: 476-81.
104. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010; 2: 26ra5.
105. Shaykhiev R, Wang R, Zwick RK, Hackett NR, Leung R, Moore MA, et al. Airway basal cells of healthy smokers express an embryonic stem cell signature relevant to lung cancer. Stem cells 2013; 31: 1992-2002.
106. Sridhar S, Schembri F, Zeskind J, Shah V, Gustafson AM, Steiling K, et al. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics 2008; 9: 259.
107. Zhang X, Sebastiani P, Liu G, Schembri F, Dumas YM, Langer EM, et al. Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiol Genomics 2010; 41: 1-8.
108. Perdomo C, Spira A, Schembri F. MiRNAs as regulators of the response to inhaled environmental toxins and airway carcinogenesis. Mutat Res 2011; 717: 32-7.
109. Schembri F, Sridhar S, Perdomo C, Gustafson AM, Zhang X, Ergun A, et al. MicroRNAs asmodulators of smoking-induced gene expression changes in human airway epithelium. Proc Natl Acad Sci U S A 2009; 106: 2319-24.
110. Perdomo C, Campbell JD, Gerrein J, Tellez CS, Garrison CB, Walser TC, et al. MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis. Proc Natl Acad Sci U S A 2013; 110: 18946-51.
111. Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, et al. Characterizing the molecular spatial and temporal field of injury in earlystage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res 2013; 6: 8-17.
112. Maki Y, Fujimoto J, Lang W, Xu L, Behrens C, Wistuba II, et al. LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2- mediated stress response pathway in lung cancer cells. Sci Rep 2015; 5: 13846.
113. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2013; 143: E142S-65S.
114. Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. Chest 2012; 142: 385-93.
115. Whitney DH, Elashoff MR, Porta-Smith K, Gower AC, Vachani A, Ferguson JS, et al. Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy. BMC Med Genomics 2015; 8: 18.
116. Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med 2015; 373: 243-51.
117. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11: 685-96.
118. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-25.
119. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 2014; 32: 121-8.
120. Beane J, Vick J, Schembri F, Anderlind C, Gower A, Campbell J, et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev Res 2011; 4: 803-17.
121. de Bruin EC, Taylor TB, Swanton C. Intra-tumor heterogeneity: Lessons from microbial evolution and clinical implications. Genome Med 2013; 5: 101.
122. Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet 2012; 13: 795-806.
123. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
124. Gorunova L, Hoglund M, Andren-Sandberg A, Dawiskiba S, Jin Y, Mitelman F, et al. Cytogenetic analysis of pancreatic carcinomas: Intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer 1998; 23: 81-99.
125. Teixeira MR, Heim S. Cytogenetic analysis of tumor clonality. Adv Cancer Res 2011; 112: 127-49.
126. Navin NE, Hicks J. Tracing the tumor lineage. Mol Oncol 2010; 4: 267-83.
127. Parker JS, Perou CM. Tumor heterogeneity: Focus on the leaves, the trees, or the forest? Cancer Cell 2015; 28: 149-50.
128. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014; 346: 256-9.
129. LaFramboise T. Single nucleotide polymorphism arrays: A decade of biological, computational and technological advances. Nucleic Acids Res 2009; 37: 4181-93.
130. Reuter JA, Spacek DV, Snyder MP. High-throughput sequencing technologies. Molecular cell 2015; 58: 586-97.
131. Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. Nat Rev Genet 2013; 14: 307-20.
132. Assie G, LaFramboise T, Platzer P, Bertherat J, Stratakis CA, Eng C. SNP arrays in heterogeneous tissue: Highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet 2008; 82: 903-15.
133. Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, et al. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Computat Biol 2006; 2: E41.
134. Li A, Liu Z, Lezon-Geyda K, Sarkar S, Lannin D, Schulz V, et al. GPHMM: An integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Res 2011; 39: 4928-41.
135. Staaf J, Lindgren D, Vallon-Christersson J, Isaksson A, Goransson H, Juliusson G, et al. Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays. Genome Biol 2008; 9: R136.
136. Vattathil S, Scheet P. Haplotype-based profiling of subtle allelic imbalance with SNP arrays. Genome Res 2013; 23: 152-8.
137. Xia R, Vattathil S, Scheet P. Identification of allelic imbalance with a statistical model for subtle genomic mosaicism. PLoS Comput Biol 2014; 10: E1003765.
138. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12: 921-7.
139. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-89.
140. Baugher JD, Baugher BD, Shirley MD, Pevsner J. Sensitive and specific detection of mosaic chromosomal abnormalities using the parent-oforigin- based detection (POD) method. BMC Genomics 2013; 14: 367.
141. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell 2012; 149: 994-1007.
142. Aberle DR, Abtin F, Brown K. Computed tomography screening for lung cancer: Has it finally arrived? Implications of the national lung screening trial. J Clin Oncol 2013; 31: 1002-8.
143. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.